<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37564648</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>14</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Microglial crosstalk with astrocytes and immune cells in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>1223096</StartPage><MedlinePgn>1223096</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1223096</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1223096</ELocationID><Abstract><AbstractText>In recent years, biomedical research efforts aimed to unravel the mechanisms involved in motor neuron death that occurs in amyotrophic lateral sclerosis (ALS). While the main causes of disease progression were first sought in the motor neurons, more recent studies highlight the gliocentric theory demonstrating the pivotal role of microglia and astrocyte, but also of infiltrating immune cells, in the pathological processes that take place in the central nervous system microenvironment. From this point of view, microglia-astrocytes-lymphocytes crosstalk is fundamental to shape the microenvironment toward a pro-inflammatory one, enhancing neuronal damage. In this review, we dissect the current state-of-the-art knowledge of the microglial dialogue with other cell populations as one of the principal hallmarks of ALS progression. Particularly, we deeply investigate the microglia crosstalk with astrocytes and immune cells reporting <i>in vitro</i> and <i>in vivo</i> studies related to ALS mouse models and human patients. At last, we highlight the current experimental therapeutic approaches that aim to modulate microglial phenotype to revert the microenvironment, thus counteracting ALS progression.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Calafatti, Cocozza, Limatola and Garofalo.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Calafatti</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cocozza</LastName><ForeName>Germana</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Limatola</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Neuromed, Pozzilli, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Sapienza University, Laboratory Affiliated to Istituto Pasteur, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garofalo</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Astrocyctes</Keyword><Keyword MajorTopicYN="N">amytrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">immune cell</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">microglia</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>11</Day><Hour>4</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37564648</ArticleId><ArticleId IdType="pmc">PMC10410456</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1223096</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goutman SA, Hardiman O, Al-Chalabi A, Chi&#xf3; A, Savelieff MG, Kiernan MC, et al. . Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. Lancet Neurol (2022) 21:465&#x2013;79. doi: 10.1016/S1474-4422(21)00414-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00414-2</ArticleId><ArticleId IdType="pmc">PMC9513754</ArticleId><ArticleId IdType="pubmed">35334234</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chio A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci (2014) 17:17&#x2013;23. doi: 10.1038/nn.3584</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3584</ArticleId><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller MF, Ferrucci L, Singleton AB, Tienari PJ, Laaksovirta H, Restagno G, et al. . Genome-wide analysis of the heritability of amyotrophic lateral sclerosis. JAMA Neurol (2014) 71:1123&#x2013;34. doi: 10.1001/jamaneurol.2014.1184</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.1184</ArticleId><ArticleId IdType="pmc">PMC4566960</ArticleId><ArticleId IdType="pubmed">25023141</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Fang F, Hanby MF, Leigh PN, Shaw CE, Ye W, et al. . An estimate of amyotrophic lateral sclerosis heritability using twin data. J Neurol Neurosurg Psychiatry (2010) 81:1324&#x2013;6. doi: 10.1136/jnnp.2010.207464</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.207464</ArticleId><ArticleId IdType="pmc">PMC2988617</ArticleId><ArticleId IdType="pubmed">20861059</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang F, Kamel F, Lichtenstein P, Bellocco R, Spar&#xe9;n P, Sandleret DP, et al. . Familial aggregation of amyotrophic lateral sclerosis. Ann Neurol (2009) 66:94&#x2013;9. doi: 10.1002/ana.21580</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21580</ArticleId><ArticleId IdType="pmc">PMC3609703</ArticleId><ArticleId IdType="pubmed">19670447</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. . Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature (1993) 362:59&#x2013;62. doi: 10.1038/362059a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R, Chio A, Traynor BJ. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol (2018) 17:94&#x2013;102. doi: 10.1016/S1474-4422(17)30401-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30401-5</ArticleId><ArticleId IdType="pmc">PMC5901717</ArticleId><ArticleId IdType="pubmed">29154141</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi Y, Homma K, Ichijo H. SOD1 in neurotoxicity and its controversial roles in SOD1 mutation-negative ALS. Adv Biol Regul (2016) 60:95&#x2013;104. doi: 10.1016/j.jbior.2015.10.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbior.2015.10.006</ArticleId><ArticleId IdType="pubmed">26563614</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, McGeer EG. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve (2002) 26:459&#x2013;70. doi: 10.1002/mus.10191</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.10191</ArticleId><ArticleId IdType="pubmed">12362410</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraiuolo L, Kirby J, Grierson AJ, Sendtner M, Shaw PJ. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol (2011) 7:616&#x2013;30. doi: 10.1038/nrneurol.2011.152</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.152</ArticleId><ArticleId IdType="pubmed">22051914</ArticleId></ArticleIdList></Reference><Reference><Citation>Hop PJ, Zwamborn RAJ, Hannon E, Shireby GL, Nabais MF, Walker EM, et al. . Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS. Sci Transl Med (2022) 14:eabj0264. doi: 10.1126/scitranslmed.abj0264</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abj0264</ArticleId><ArticleId IdType="pmc">PMC10040186</ArticleId><ArticleId IdType="pubmed">35196023</ArticleId></ArticleIdList></Reference><Reference><Citation>Dal Canto MC, Gurney ME. Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis. Am J Pathol (1994) 145:1271&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887498</ArticleId><ArticleId IdType="pubmed">7992831</ArticleId></ArticleIdList></Reference><Reference><Citation>Boill&#xe9;e S. Onset and progression in inherited ALS determined by motor neurons and microglia. Science (2006) 312:1389&#x2013;92. doi: 10.1126/science.1123511</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1123511</ArticleId><ArticleId IdType="pubmed">16741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosco DA, Morfini G, Karabacak N.M, Song Y, Gros-Louis F, Pasinelli P, et al. . Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci (2010) 13:1396&#x2013;403. doi: 10.1038/nn.2660</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2660</ArticleId><ArticleId IdType="pmc">PMC2967729</ArticleId><ArticleId IdType="pubmed">20953194</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska I. TDP-43 mutant mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci (2009) 106:18809&#x2013;14. doi: 10.1073/pnas.0908767106</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0908767106</ArticleId><ArticleId IdType="pmc">PMC2762420</ArticleId><ArticleId IdType="pubmed">19833869</ArticleId></ArticleIdList></Reference><Reference><Citation>Suk TR, Rousseaux MWC. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Mol Neurodegener (2020) 15:45. doi: 10.1186/s13024-020-00397-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00397-1</ArticleId><ArticleId IdType="pmc">PMC7429473</ArticleId><ArticleId IdType="pubmed">32799899</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Rousseaux MWC. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron (2011) 72:257&#x2013;68. doi: 10.1016/j.neuron.2011.09.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. . Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron (2011) 72:245&#x2013;56. doi: 10.1016/j.neuron.2011.09.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebbert MTW, Farrugia SL, Sens JP, Jansen-West K, Gendron TF, Prudencio M, et al. . Long-read sequencing across the C9orf72 &#x2018;GGGGCC&#x2019; repeat expansion: implications for clinical use and genetic discovery efforts in human disease. Mol Neurodegener (2018) 13:46. doi: 10.1186/s13024-018-0274-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0274-4</ArticleId><ArticleId IdType="pmc">PMC6102925</ArticleId><ArticleId IdType="pubmed">30126445</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciura S, Lattante S, Le Ber I, Latouche M, Tostivint H, Brice A, et al. . Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. Ann Neurol (2013) 74:180&#x2013;7. doi: 10.1002/ana.23946</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23946</ArticleId><ArticleId IdType="pubmed">23720273</ArticleId></ArticleIdList></Reference><Reference><Citation>Therrien M, Rouleau GA, Dion PA, Parker JA. Deletion of C9ORF72 results in motor neuron degeneration and stress sensitivity in c. elegans. PloS One (2013) 8:e83450. doi: 10.1371/journal.pone.0083450</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0083450</ArticleId><ArticleId IdType="pmc">PMC3861484</ArticleId><ArticleId IdType="pubmed">24349511</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelvig DP, Pakkenberg H, Stark AK, Pakkenberg B. Neocortical glial cell numbers in human brains. Neurobiol Aging (2008) 29:1754&#x2013;62. doi: 10.1016/j.neurobiolaging.2007.04.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.04.013</ArticleId><ArticleId IdType="pubmed">17544173</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda T, Amann L, Monaco G, Sankowski R, Staszewski O, Krueger M, et al. . Specification of CNS macrophage subsets occurs postnatally in defined niches. Nature (2022) 604:740&#x2013;8. doi: 10.1038/s41586-022-04596-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04596-2</ArticleId><ArticleId IdType="pubmed">35444273</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawson LJ, Perry VH, Dri P, Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience (1990) 39:151&#x2013;70. doi: 10.1016/0306-4522(90)90229-W</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0306-4522(90)90229-W</ArticleId><ArticleId IdType="pubmed">2089275</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol (2009) 27:119&#x2013;45. doi: 10.1146/annurev.immunol.021908.132528</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.021908.132528</ArticleId><ArticleId IdType="pubmed">19302036</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruttger J, Karram K, W&#xf6;rtge S, Regen T, Marini F, Hoppmann N, et al. . Genetic cell ablation reveals clusters of local self-renewing microglia in the mammalian central nervous system. Immunity (2015) 43:92&#x2013;106. doi: 10.1016/j.immuni.2015.06.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2015.06.012</ArticleId><ArticleId IdType="pubmed">26163371</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM. A polarizing question: do M1 and M2 microglia exist? nat. Neurosci. (2016) 19:987&#x2013;91. doi:&#xa0;10.1038/nn.4338</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4338</ArticleId><ArticleId IdType="pubmed">27459405</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond BP, Manek R, Kerr BJ, Macauley MS, Plemel JR. Regulation of microglia population dynamics throughout development, health, and disease. Glia (2021) 69(12):2771&#x2013;97. doi: 10.1002/glia.24047</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.24047</ArticleId><ArticleId IdType="pubmed">34115410</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond TR, Robinton D, Stevens B. Microglia and the brain: complementary partners in development and disease. Annu Rev Cell Dev Biol (2018) 34:523&#x2013;44. doi: 10.1146/annurev-cellbio-100616-060509</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-cellbio-100616-060509</ArticleId><ArticleId IdType="pubmed">30089221</ArticleId></ArticleIdList></Reference><Reference><Citation>Zia S, Rawji KS, Michaels NJ, Burr M, Kerr BJ, Healy LM, et al. . Microglia diversity in health and multiple sclerosis. Front Immunol (2020) 11:588021. doi: 10.3389/fimmu.2020.588021</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.588021</ArticleId><ArticleId IdType="pmc">PMC7677361</ArticleId><ArticleId IdType="pubmed">33240276</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda T, Sankowski R, Staszewski O, Prinz M. Microglia heterogeneity in the single-cell era. Cell Rep (2020) 30:1271&#x2013;81. doi: 10.1016/j.celrep.2020.01.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.01.010</ArticleId><ArticleId IdType="pubmed">32023447</ArticleId></ArticleIdList></Reference><Reference><Citation>Deczkowska A, Amit I, Schwartz M. Microglial immune checkpoint mechanisms. Nat Neurosci (2018) . 21:6. doi: 10.1038/s41593-018-0145-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0145-x</ArticleId><ArticleId IdType="pubmed">29735982</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown GC, Neher JJ. Microglial phagocytosis of live neurons. Nat Rev Neurosci (2014) 15:209&#x2013;16. doi: 10.1038/nrn3710</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3710</ArticleId><ArticleId IdType="pubmed">24646669</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer DP, Stevens B. Phagocytic glial cells: sculpting synaptic circuits in the developing nervous system. Curr Opin Neurobiol (2013) 23:1034&#x2013;40. doi: 10.1016/j.conb.2013.09.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2013.09.012</ArticleId><ArticleId IdType="pmc">PMC3907950</ArticleId><ArticleId IdType="pubmed">24157239</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremblay ME, Lowery RL, Majewska AK. Microglial interactions with synapses are modulated by visual experience. PloS Biol (2010) 8:e1000527. doi: 10.1371/journal.pbio.1000527</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.1000527</ArticleId><ArticleId IdType="pmc">PMC2970556</ArticleId><ArticleId IdType="pubmed">21072242</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P, et al. . Synaptic pruning by microglia is necessary for normal brain development. Science (2011) 333:1456&#x2013;8. doi: 10.1126/science.1202529</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1202529</ArticleId><ArticleId IdType="pubmed">21778362</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes AN, Appel B. Microglia phagocytose myelin sheaths to modify developmental myelination. Nat Neurosci (2020) 23(9):1055&#x2013;1066. doi: 10.1038/s41593-020-0654-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-0654-2</ArticleId><ArticleId IdType="pmc">PMC7483351</ArticleId><ArticleId IdType="pubmed">32632287</ArticleId></ArticleIdList></Reference><Reference><Citation>Lloyd AF, Davies CL, Holloway RK, Labrak Y, Ireland G, Carradori D, et al. . Central nervous system regeneration is driven by microglia necroptosis and repopulation. Nat Neurosci (2019) 22(7):1046&#x2013;1052. doi: 10.1038/s41593-019-0418-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0418-z</ArticleId><ArticleId IdType="pmc">PMC6597360</ArticleId><ArticleId IdType="pubmed">31182869</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore CS, Ase AR, Kinsara A, Rao VTS, Michell-Robinson M, Leong SY, et al. . P2Y12 expression and function in alternatively activated human microglia. Neurol Neuroimmunol Neuroinflamm (2015) 2:e80. doi: 10.1212/NXI.0000000000000080</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000080</ArticleId><ArticleId IdType="pmc">PMC4370387</ArticleId><ArticleId IdType="pubmed">25821842</ArticleId></ArticleIdList></Reference><Reference><Citation>Riazi K, Galic MA, Kentner AC, Reid AY, Sharkey KA, Pittman QJ, et al. . Microglia-dependent alteration of glutamatergic synaptic transmission and plasticity in the hippocampus during peripheral inflammation. J Neurosci (2015) 35:4942&#x2013;52. doi: 10.1523/JNEUROSCI.4485-14.2015</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4485-14.2015</ArticleId><ArticleId IdType="pmc">PMC6705378</ArticleId><ArticleId IdType="pubmed">25810524</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, Naj AC, Jun G, Reitz C, Kunkle BW, Perry W, et al. . Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study. JAMA Neurol (2014) 71:1394&#x2013;404. doi: 10.1001/jamaneurol.2014.1491</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.1491</ArticleId><ArticleId IdType="pmc">PMC4314944</ArticleId><ArticleId IdType="pubmed">25199842</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Weiner HL. Microglial signatures and their role in health and disease. Nat Rev Neurosci (2018) 19:622&#x2013;35. doi: 10.1038/s41583-018-0057-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41583-018-0057-5</ArticleId><ArticleId IdType="pmc">PMC7255106</ArticleId><ArticleId IdType="pubmed">30206328</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda T, Sankowski R, Staszewski O, Bottcher C, Amann L, Sagar et al. . Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution. Nature (2019) 566(7744):388&#x2013;392. doi: 10.1038/s41586-019-0924-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-0924-x</ArticleId><ArticleId IdType="pubmed">30760929</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, et al. . The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity (2017) 47(3):566&#x2013;581 e569. doi: 10.1016/j.immuni.2017.08.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2017.08.008</ArticleId><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med (2012) 2:a006346. doi: 10.1101/cshperspect.a006346</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a006346</ArticleId><ArticleId IdType="pmc">PMC3253025</ArticleId><ArticleId IdType="pubmed">22315714</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol (2020) 17:157&#x2013;172. doi: 10.1038/s41582-020-00435-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-00435-y</ArticleId><ArticleId IdType="pubmed">33318676</ArticleId></ArticleIdList></Reference><Reference><Citation>Gushchina S, Pryce G, Yip PK, Wu D, Pallier P, Giovannoni G, et al. . Increased expression of colony-stimulating factor-1 in mouse spinal cord with experimental autoimmune encephalomyelitis correlates with microglial activation and neuronal loss. Glia (2018) 66(10):2108&#x2013;2125. doi: 10.1002/glia.23464</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23464</ArticleId><ArticleId IdType="pubmed">30144320</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging alzheimer&#x2019;s disease mice. J Neurosci (2008) 28:8354&#x2013;60. doi: 10.1523/JNEUROSCI.0616-08.2008</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0616-08.2008</ArticleId><ArticleId IdType="pmc">PMC2597474</ArticleId><ArticleId IdType="pubmed">18701698</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao B, Zhao W, Beers DR, Henkel JS, Appel SH. Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp Neurol (2012) 237:147&#x2013;52. doi: 10.1016/j.expneurol.2012.06.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2012.06.011</ArticleId><ArticleId IdType="pmc">PMC4126417</ArticleId><ArticleId IdType="pubmed">22735487</ArticleId></ArticleIdList></Reference><Reference><Citation>Muzio L, Martino G, Furlan R. Multifaceted aspects of inflammation in multiple sclerosis: the role of microglia. J Neuroimmunol (2007) 191:39&#x2013;44. doi: 10.1016/j.jneuroim.2007.09.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2007.09.016</ArticleId><ArticleId IdType="pubmed">17936915</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury J, Hickman SE, Thomas CA, Cao L, Silverstein SC, Loike JD. Scavenger receptor-mediated adhesion of microglia to beta-amyloid fbrils. Nature (1996) 382:716&#x2013;9. doi: 10.1038/382716a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/382716a0</ArticleId><ArticleId IdType="pubmed">8751442</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, Kingery ND, Ohsumi TK, Borowsky ML, Wang L, Means TK, et al. . The microglial sensome revealed by direct RNA sequencing. Nat Neurosci (2013) 16:1896&#x2013;905. doi: 10.1038/nn.3554</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3554</ArticleId><ArticleId IdType="pmc">PMC3840123</ArticleId><ArticleId IdType="pubmed">24162652</ArticleId></ArticleIdList></Reference><Reference><Citation>Saijo K, Crotti A, Glass CK. Regulation of microglia activation and deactivation by nuclear receptors. Glia (2013) 61:104&#x2013;11. doi: 10.1002/glia.22423</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22423</ArticleId><ArticleId IdType="pubmed">22987512</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Golenbock DT, Latz E. Innate immunity in alzheimer&#x2019;s disease. Nat Immunol (2015) 16:229&#x2013;36. doi: 10.1038/ni.3102</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3102</ArticleId><ArticleId IdType="pubmed">25689443</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Chen ZJ. Innate immune sensing and signaling of cytosolic nucleic acids. Annu Rev Immunol (2014) 32:461&#x2013;88. doi: 10.1146/annurev-immunol-032713-120156</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-032713-120156</ArticleId><ArticleId IdType="pubmed">24655297</ArticleId></ArticleIdList></Reference><Reference><Citation>Areschoug T, Gordon S. Scavenger receptors: role in innate immunity and microbial pathogenesis. Cell Microbiol (2009) 11:1160&#x2013;9. doi: 10.1111/j.1462-5822.2009.01326.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1462-5822.2009.01326.x</ArticleId><ArticleId IdType="pubmed">19388903</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel SH, Zhao W, Beers DR, Henkel JS. The microglial-motoneuron dialogue in ALS. Acta Myol (2011) 30:4&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3185827</ArticleId><ArticleId IdType="pubmed">21842586</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohof RM, El Khoury J. Microglia in health and disease. Cold Spring Harb Perspect Biol (2015) 8:a020560. doi:&#xa0;10.1101/cshperspect.a020560</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a020560</ArticleId><ArticleId IdType="pmc">PMC4691795</ArticleId><ArticleId IdType="pubmed">26354893</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman S, Izzy S, Sen P, Morsett L, El Khoury J. Microglia in neurodegeneration. Nat Neurosci (2018) 21:1359&#x2013;69. doi: 10.1038/s41593-018-0242-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0242-x</ArticleId><ArticleId IdType="pmc">PMC6817969</ArticleId><ArticleId IdType="pubmed">30258234</ArticleId></ArticleIdList></Reference><Reference><Citation>Bemiller SM, McCray TJ, Allan K, Formica SV, Xu G, Wilson G, et al. . TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy. Mol Neurodegener (2017) 12:74. doi: 10.1186/s13024-017-0216-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0216-6</ArticleId><ArticleId IdType="pmc">PMC5644120</ArticleId><ArticleId IdType="pubmed">29037207</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. . Variant of TREM2 associated with the risk of alzheimer&#x2019;s disease. N Engl J Med (2013) 368:107&#x2013;16. doi: 10.1056/NEJMoa1211103</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211103</ArticleId><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh R, Tabrizi SJ. Huntington disease. Handb Clin Neurol (2018) 147:255&#x2013;78. doi: 10.1016/B978-0-444-63233-3.00017-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-444-63233-3.00017-8</ArticleId><ArticleId IdType="pubmed">29325616</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, Tauber C, Vercoullie J, Arlicot N, Prunier C, Praline J, et al. . Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PloS One (2012) 7:e52941. doi: 10.1371/journal.pone.0052941</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0052941</ArticleId><ArticleId IdType="pmc">PMC3534121</ArticleId><ArticleId IdType="pubmed">23300829</ArticleId></ArticleIdList></Reference><Reference><Citation>Brites D, Vaz AR. Microglia centered pathogenesis in ALS: insights in cell interconnectivity. Front Cell Neurosci (2014) 8:117. doi: 10.3389/fncel.2014.00117</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00117</ArticleId><ArticleId IdType="pmc">PMC4033073</ArticleId><ArticleId IdType="pubmed">24904276</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM, Schafer D, Vincent A, Blachere NE, Bar-Or A. Neuroinflammation: ways in which the immune system affects the brain. Neurotherapeutics (2015) 12:896&#x2013;909. doi: 10.1007/s13311-015-0385-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-015-0385-3</ArticleId><ArticleId IdType="pmc">PMC4604183</ArticleId><ArticleId IdType="pubmed">26306439</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Engelhardt JI, Siklos L, Simpson EP, Kim SH, Pan T, et al. . Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol (2004) 55:221&#x2013;35. doi:&#xa0;10.1002/ana.10805</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10805</ArticleId><ArticleId IdType="pubmed">14755726</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Cagnin A, Turkheimer FE, Miller CC, Shaw CE, Brooks DJ, et al. . Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis (2004) 15:601&#x2013;9. doi:&#xa0;10.1016/j.nbd.2003.12.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2003.12.012</ArticleId><ArticleId IdType="pubmed">15056468</ArticleId></ArticleIdList></Reference><Reference><Citation>Zurcher NR, Loggia ML, Lawson R, Chonde DB, Izquierdo-Garcia D, et al. . Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [11C]-PBR28. NeuroImage Clin (2015) 7:409&#x2013;14. doi: 10.1016/j.nicl.2015.01.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2015.01.009</ArticleId><ArticleId IdType="pmc">PMC4310932</ArticleId><ArticleId IdType="pubmed">25685708</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu I, Morimoto EA, Goodarzi H, Liao J, O&#x2019;Keeffe S, Phatnani H, et al. . A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Rep (2013) 4(2):385&#x2013;401. doi: 10.1016/j.celrep.2013.06.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2013.06.018</ArticleId><ArticleId IdType="pmc">PMC4272581</ArticleId><ArticleId IdType="pubmed">23850290</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke BE, Patani R. The microglial component of amyotrophic lateral sclerosis. Brain (2020) 12:3526&#x2013;39. doi: 10.1093/brain/awaa309</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa309</ArticleId><ArticleId IdType="pmc">PMC7805793</ArticleId><ArticleId IdType="pubmed">33427296</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR. Neuroinflammation modulates distinct regional and temporal clinical responses in ALS mice. Brain Behav Immun (2011) 25:1025&#x2013;35. doi: 10.1016/j.bbi.2010.12.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2010.12.008</ArticleId><ArticleId IdType="pmc">PMC3096756</ArticleId><ArticleId IdType="pubmed">21176785</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Henkel JS, Xiao Q, Zhao W, Wang J, Yen AA, et al. . Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U.S.A (2006) 103(43):16021&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1613228</ArticleId><ArticleId IdType="pubmed">17043238</ArticleId></ArticleIdList></Reference><Reference><Citation>Salter MW. Microglia emerge as central players in brain disease. Nat Med (2017) 23:1018&#x2013;27. doi: 10.1038/nm.4397</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4397</ArticleId><ArticleId IdType="pubmed">28886007</ArticleId></ArticleIdList></Reference><Reference><Citation>Deczkowska A. Disease-associated microglia: a universal immune sensor of neurodegeneration. Cell (2018) 173:1073&#x2013;81. doi: 10.1016/j.cell.2018.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.05.003</ArticleId><ArticleId IdType="pubmed">29775591</ArticleId></ArticleIdList></Reference><Reference><Citation>Frakes AE, Ferraiuolo L, Haidet-Phillips AM, Schmelzer L, Braun L, Miranda CJ, et al. . Microglia induce motor neuron death via the classical NF-&#x3ba;B pathway in amyotrophic lateral sclerosis. Neuron (2014) 81:1009&#x2013;23. doi: 10.1016/j.neuron.2014.01.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.01.013</ArticleId><ArticleId IdType="pmc">PMC3978641</ArticleId><ArticleId IdType="pubmed">24607225</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff JR, Gao J, Dunn TJ, Ojeda L, Wu P. Mutant SOD1 microglia-generated nitroxidative stress promotes toxicity to human fetal neural stem cellderived motor neurons through direct damage and noxious interactions with astrocytes. Am J Stem Cells (2011) 19:2&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3643388</ArticleId><ArticleId IdType="pubmed">23671793</ArticleId></ArticleIdList></Reference><Reference><Citation>Cocozza G, Garofalo S, Morotti M, Chece G, Grimaldi A, Lecce M, et al. . The feeding behaviour of amyotrophic lateral sclerosis mouse models is modulated by the Ca2+ -activated KCa 3.1 channels. Br J Pharmacol (2021) 178(24):4891&#x2013;906. doi: 10.1111/bph.15665</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15665</ArticleId><ArticleId IdType="pmc">PMC9293222</ArticleId><ArticleId IdType="pubmed">34411281</ArticleId></ArticleIdList></Reference><Reference><Citation>Parisi C, Arisi I, D&#x2019;Ambrosi N, Storti AE, Brandi R, D&#x2019;Onofrio M, et al. . Dysregulated microRNAs in amyotrophic lateral sclerosis microglia modulate genes linked to neuroinflammation. Cell Death Dis (2013) 12:e959. doi: 10.1038/cddis.2013.491</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2013.491</ArticleId><ArticleId IdType="pmc">PMC3877562</ArticleId><ArticleId IdType="pubmed">24336079</ArticleId></ArticleIdList></Reference><Reference><Citation>Cocozza G, di Castro MA, Carbonari L, Grimaldi A, Antonangeli F, Garofalo S, et al. . Ca2+-activated k+ channels modulate microglia affecting motor neuron survival in hSOD1G93A mice. Brain Behav Immun (2018) 73:584&#x2013;95. doi: 10.1016/j.bbi.2018.07.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2018.07.002</ArticleId><ArticleId IdType="pmc">PMC6129409</ArticleId><ArticleId IdType="pubmed">29981425</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiller KJ, Restrepo CR, Khan T, Dominique MA, Fang TC, Canter RG, et al. . Microglia-mediated recovery from ALS-relevant motor neuron degeneration in a mouse model of TDP-43 proteinopathy. Nat Neurosci (2018) 21:329&#x2013;40. doi: 10.1038/s41593-018-0083-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0083-7</ArticleId><ArticleId IdType="pmc">PMC5857237</ArticleId><ArticleId IdType="pubmed">29463850</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E, Renton AE, Mok K, Dopper EG, Waite A, Rollinson S, et al. . Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol (2012) 11:323&#x2013;30. doi: 10.1016/S1474-4422(12)70043-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70043-1</ArticleId><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Belzil VV, Bauer PO, Prudencio M, Gendron TF, Stetler CT, Yan IK, et al. . Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood. Acta Neuropathol (2013) 126:895&#x2013;905. doi: 10.1007/s00401-013-1199-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1199-1</ArticleId><ArticleId IdType="pmc">PMC3830740</ArticleId><ArticleId IdType="pubmed">24166615</ArticleId></ArticleIdList></Reference><Reference><Citation>Gijselinck I, Van Langenhove T, van der Zee J, Sleegers K, Philtjens S, Kleinberger G, et al. . A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol (2012) 11:54&#x2013;65. doi: 10.1016/S1474-4422(11)70261-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(11)70261-7</ArticleId><ArticleId IdType="pubmed">22154785</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta P, Poulter M, Lashley T, Rohrer JD, Polke J. M, Beck J, et al. . Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia. Acta Neuropathol (2013) 126:401&#x2013;9. doi: 10.1007/s00401-013-1147-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1147-0</ArticleId><ArticleId IdType="pmc">PMC3753468</ArticleId><ArticleId IdType="pubmed">23818065</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi Z, Zinman L, Moreno D, Schymick J, Liang Y, Sato C, et al. . Hypermethylation of the CpG island near the G4C2 repeat in ALS with a C9orf72 expansion. Am J Hum Genet (2013) 92:981&#x2013;9. doi: 10.1016/j.ajhg.2013.04.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2013.04.017</ArticleId><ArticleId IdType="pmc">PMC3675239</ArticleId><ArticleId IdType="pubmed">23731538</ArticleId></ArticleIdList></Reference><Reference><Citation>Waite AJ, Baumer D, East S, Neal J, Morris HR, Ansorge O, et al. . Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal degeneration brain with the C9ORF72 hexanucleotide repeat expansion. Neurobiol Aging (2014) 35:1779.e5&#x2013;1779.e13. doi: 10.1016/j.neurobiolaging.2014.01.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.01.016</ArticleId><ArticleId IdType="pmc">PMC3988882</ArticleId><ArticleId IdType="pubmed">24559645</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke JG, Bogdanik L, Y&#xe1;&#xf1;ez A, Lall D, Wolf AJ, Muhammad AKMG, et al. . C9orf72 is required for proper macrophage and microglial function in mice. Science (2016) 351:1324&#x2013;9. doi: 10.1126/science.aaf1064</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf1064</ArticleId><ArticleId IdType="pmc">PMC5120541</ArticleId><ArticleId IdType="pubmed">26989253</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly CJ, Zhang PW, Pham JT, Haeusler AR, Mistry NA, Vidensky S, et al. . RNA Toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron (2013) 80:415&#x2013;28. doi: 10.1016/j.neuron.2013.10.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.10.015</ArticleId><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Sareen D, O'Rourke JG, Meera P, Muhammad AKMG, Grant S, Simpkinson M, et al. . Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci Trans Med (2013) 5:208ra149. doi: 10.1126/scitranslmed.3007529</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3007529</ArticleId><ArticleId IdType="pmc">PMC4090945</ArticleId><ArticleId IdType="pubmed">24154603</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PEA, Bieniek KF, Gendron TF, Caulfield T, Lin WL, Dejesus-Hernandez M, et al. . Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron (2013) 77:639&#x2013;46. doi: 10.1016/j.neuron.2013.02.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.02.004</ArticleId><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, Liu Y, Banez-Coronel M, Reid T, Pletnikova O, Lewis J, et al. . RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci USA (2013) 110:E4968&#x2013;77. doi: 10.1073/pnas.1315438110</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1315438110</ArticleId><ArticleId IdType="pmc">PMC3870665</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. . Neurotoxic reactive astrocytes are induced by activated microglia. Nature (2017) 541:481&#x2013;7. doi:&#xa0;10.1038/nature21029</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature21029</ArticleId><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Phani S, Re DB, Przedborski S. The role of the innate immune system in ALS. Front Pharmacol (2012) 3:150. doi:&#xa0;10.3389/fphar.2012.00150</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2012.00150</ArticleId><ArticleId IdType="pmc">PMC3418523</ArticleId><ArticleId IdType="pubmed">22912616</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamata T, Akiyama H, Yamada T, McGeer PL. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol (1992) 140:691&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886170</ArticleId><ArticleId IdType="pubmed">1347673</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffer D, Cordera S, Cavalla P, Migheli A. Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis. J Neurol Sci (1996) 139:27&#x2013;33. doi: 10.1016/0022-510X(96)00073-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(96)00073-1</ArticleId><ArticleId IdType="pubmed">8899654</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy D, Kato T, Kushner PD. Reactive astrocytes are widespread in the cortical gray matter of amyotrophic lateral sclerosis. J Neurosci Res (1994) 38:336&#x2013;47. doi: 10.1002/jnr.490380312</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.490380312</ArticleId><ArticleId IdType="pubmed">7523689</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson A, Engler H, Blomquist G, Scott B, Wall A, et al. . Evidence for astrocytosis in ALS demonstrated by [11C](L)-deprenyl-D2 PET. J Neurol Sci (2007) 255:17&#x2013;22. doi: 10.1016/j.jns.2007.01.057</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2007.01.057</ArticleId><ArticleId IdType="pubmed">17346749</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouali Alami N, Schurr C, Olde Heuvel F, Tang L, Li Q, Tasdogan A, et al. . NF-&#x3ba;B activation in astrocytes drives a stage-specific beneficial neuroimmunological response in ALS. EMBO J (2018) 37:e98697. doi:&#xa0;10.15252/embj.201798697</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201798697</ArticleId><ArticleId IdType="pmc">PMC6092622</ArticleId><ArticleId IdType="pubmed">29875132</ArticleId></ArticleIdList></Reference><Reference><Citation>Guttenplan KA, Weigel MK, Adler DI, Couthouis J, Liddelow SA, Gitler AD, et al. . Knockout of reactive astrocyte activating factors slows disease progression in an ALS mouse model. Nat Commun (2020) 11:3753. doi:&#xa0;10.1038/s41467-020-17514-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17514-9</ArticleId><ArticleId IdType="pmc">PMC7385161</ArticleId><ArticleId IdType="pubmed">32719333</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng AYT, et al. . Loss of TDP-43 in astrocytes leads to motor deficits by triggering A1-like reactive phenotype and triglial dysfunction. Proc Natl Acad Sci USA (2020) 117:29101&#x2013;12. doi: 10.1073/pnas.2007806117</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2007806117</ArticleId><ArticleId IdType="pmc">PMC7682406</ArticleId><ArticleId IdType="pubmed">33127758</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang LL, Zhu B, Zhao Y, Li X, Liu T, Pina-Crespo J, et al. . Membralin deficiency dysregulates astrocytic glutamate homeostasis leading to ALS-like impairment. J Clin Invest (2019) 129:3103&#x2013;20. doi: 10.1172/JCI127695</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI127695</ArticleId><ArticleId IdType="pmc">PMC6668683</ArticleId><ArticleId IdType="pubmed">31112137</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexianu ME, Kozovska M, Appel SH. Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology (2001) 57:1282&#x2013;9. doi:&#xa0;10.1212/WNL.57.7.1282</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.57.7.1282</ArticleId><ArticleId IdType="pubmed">11591849</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang WW, Sidman RL, Taksir TV, Treleaven CM, Fidler JA, Cheng SH. Relationship between neuropathology and disease pro- gression in the SOD1(G93A) ALS mouse. Exp Neurol (2011) 227:287&#x2013;95. doi:&#xa0;10.1016/j.expneurol.2010.11.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2010.11.019</ArticleId><ArticleId IdType="pubmed">21145892</ArticleId></ArticleIdList></Reference><Reference><Citation>Endo F, Komine O, Fujimori-Tonou N, Katsuno M, Jin S, Watanabe S, et al. . Astrocyte-derived TGF-&#x3b2;1 accelerates disease progression in ALS mice by interfering with the neuroprotective functions of microglia and T cells. Cell Rep (2015) 11(4):592&#x2013;604. doi:&#xa0;10.1016/j.celrep.2015.03.053</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.03.053</ArticleId><ArticleId IdType="pubmed">25892237</ArticleId></ArticleIdList></Reference><Reference><Citation>Brites D. The evolving landscape of neurotoxicity by unconjugated bilirubin: role of glial cells and inflammation. Front Pharmacol (2012) 3:88. doi:&#xa0;10.3389/fphar.2012.00088</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2012.00088</ArticleId><ArticleId IdType="pmc">PMC3361682</ArticleId><ArticleId IdType="pubmed">22661946</ArticleId></ArticleIdList></Reference><Reference><Citation>Meme W, Calvo CF, Froger N, Ezan P, Amigou E, Koulakoff A, et al. . Proinflammatory cytokines released from microglia inhibit gap junc- tions in astrocytes: potentiation by beta-amyloid. FASEB J (2006) 20:494&#x2013;6. doi:&#xa0;10.1096/fj.05-4297fje</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.05-4297fje</ArticleId><ArticleId IdType="pubmed">16423877</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, Zhou T, Kashlan SR, Little RJ, Goutman SA, Feldman EL. Correlation of peripheral immunity with rapid amyotrophic lateral sclerosis progression. JAMA Neurol (2017) 74(12):1446&#x2013;54. doi:&#xa0;10.1001/jamaneurol.2017.2255</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.2255</ArticleId><ArticleId IdType="pmc">PMC5822195</ArticleId><ArticleId IdType="pubmed">28973548</ArticleId></ArticleIdList></Reference><Reference><Citation>Garofalo S, Cocozza G, Porzia A, Inghilleri M, Raspa M, Scavizzi F, et al. . Natural killer cells modulate motor neuron-immune cell cross talk in models of amyotrophic lateral sclerosis. Nat Commun (2020) 11(1):1773. doi:&#xa0;10.1038/s41467-020-15644-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15644-8</ArticleId><ArticleId IdType="pmc">PMC7156729</ArticleId><ArticleId IdType="pubmed">32286313</ArticleId></ArticleIdList></Reference><Reference><Citation>Garofalo S, Cocozza G, Bernardini G, Savage J, Raspa M, Aronica E, et al. . Blocking immune cell infiltration of the central nervous system to tame neuroinflammation in amyotrophic lateral sclerosis. Brain Behav Immun (2022) 105:1&#x2013;14. doi:&#xa0;10.1016/j.bbi.2022.06.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2022.06.004</ArticleId><ArticleId IdType="pubmed">35688338</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y, Sch&#xfc;rpf T, Springer TA. How natalizumab binds and antagonizes &#x3b1;4 integrins. J Biol Chem (2013) 45:32314&#x2013;25. doi: 10.1074/jbc.M113.501668</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.501668</ArticleId><ArticleId IdType="pmc">PMC3820868</ArticleId><ArticleId IdType="pubmed">24047894</ArticleId></ArticleIdList></Reference><Reference><Citation>Gan Y, Liu R, Wu W, Bomprezzi R, Shi FD. Antibody to &#x3b1;4 integrin suppresses natural killer cells infiltration in central nervous system in experimental autoimmune encephalomyelitis. J Neuroimmunol (2012) 247:9&#x2013;15. doi: 10.1016/j.jneuroim.2012.03.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2012.03.011</ArticleId><ArticleId IdType="pmc">PMC3351567</ArticleId><ArticleId IdType="pubmed">22503411</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt B, Ransohoff RM. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol (2005) 26(9):485&#x2013;95. doi: 10.1016/j.it.2005.07.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2005.07.004</ArticleId><ArticleId IdType="pubmed">16039904</ArticleId></ArticleIdList></Reference><Reference><Citation>Matejuk A, Vandenbark AA, Offner H. Cross-talk of the CNS with immune cells and functions in health and disease. Front Neurol (2021) 12:672455. doi:&#xa0;10.3389/fneur.2021.672455</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.672455</ArticleId><ArticleId IdType="pmc">PMC8200536</ArticleId><ArticleId IdType="pubmed">34135852</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt JI, Tajti J, Appel SH. Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch Neurol (1993) 50:30&#x2013;6. doi: 10.1001/archneur.1993.00540010026013</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1993.00540010026013</ArticleId><ArticleId IdType="pubmed">8093428</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala M, Chattopadhay M, La Cava A, Tse E, Liu G, Lourenco E, et al. . IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients. J Neuroinflammation (2010) 7:76. doi: 10.1186/1742-2094-7-76</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-7-76</ArticleId><ArticleId IdType="pmc">PMC2992053</ArticleId><ArticleId IdType="pubmed">21062492</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Henkel JS, Zhao W, Wang J, Appel SH. CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc Natl Acad Sci USA (2008) 105:15558&#x2013;63. doi: 10.1073/pnas.0807419105</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0807419105</ArticleId><ArticleId IdType="pmc">PMC2547419</ArticleId><ArticleId IdType="pubmed">18809917</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu IM, Chen A, Zheng Y, Kosaras B, Tsiftsoglou SA, et al. . T Lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc Natl Acad Sci USA (2008) 105:17913&#x2013;8. doi: 10.1073/pnas.0804610105</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0804610105</ArticleId><ArticleId IdType="pmc">PMC2581614</ArticleId><ArticleId IdType="pubmed">18997009</ArticleId></ArticleIdList></Reference><Reference><Citation>Kipnis J, Schwartz M. Controlled autoimmunity in CNS maintenance and repair: naturally occurring CD4+CD25+ regulatory T cells at the crossroads of health and disease. Neuromol Med (2005) 7:197&#x2013;206. doi: 10.1385/NMM:7:3:197</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/NMM:7:3:197</ArticleId><ArticleId IdType="pubmed">16247180</ArticleId></ArticleIdList></Reference><Reference><Citation>Coque E, Salsac C, Espinosa-Carrasco G, Varga B, Degauque N, Cadoux M, et al. . Cytotoxic CD8+ T lymphocytes expressing ALS-causing SOD1 mutant selectively trigger death of spinal motoneurons. Proc Natl Acad Sci U S A (2019) 116(6):2312&#x2013;7. doi: 10.1073/pnas.1815961116</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1815961116</ArticleId><ArticleId IdType="pmc">PMC6369778</ArticleId><ArticleId IdType="pubmed">30674678</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo G, Trolese MC, Verderio M, Mariani A, De Paola M, Riva N, et al. . Counteracting roles of MHCI and CD8+ T cells in the peripheral and central nervous system of ALS SOD1G93A mice. Mol Neurodegener (2018) 13(1):42. doi:&#xa0;10.1186/s13024-018-0271-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0271-7</ArticleId><ArticleId IdType="pmc">PMC6085701</ArticleId><ArticleId IdType="pubmed">30092791</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirahara K, Nakayama T. CD4+ T-cell subsets in inflammatory diseases: beyond the Th1/Th2 paradigm. Int Immunol (2016) 28(4):163&#x2013;71. doi:&#xa0;10.1093/intimm/dxw006</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/dxw006</ArticleId><ArticleId IdType="pmc">PMC4889886</ArticleId><ArticleId IdType="pubmed">26874355</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Henkel JS, Zhao W, Wang J, Huang A, Wen S, et al. . Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain (2011) 134(Pt 5):1293&#x2013;314. doi:&#xa0;10.1093/brain/awr074</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr074</ArticleId><ArticleId IdType="pmc">PMC3097891</ArticleId><ArticleId IdType="pubmed">21596768</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Zhao W, Wang J, Zhang X, Wen S, Neal D, et al. . ALS patients&#x2019; regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI Insight (2017) 2:e89530. doi:&#xa0;10.1172/jci.insight.89530</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.89530</ArticleId><ArticleId IdType="pmc">PMC5333967</ArticleId><ArticleId IdType="pubmed">28289705</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Beers DR, Zhao W, Appel SH. Microglia in ALS: the good, the bad, and the resting. J Neuroimmune Pharmacol (2009) 4:389&#x2013;98. doi:&#xa0;10.1007/s11481-009-9171-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-009-9171-5</ArticleId><ArticleId IdType="pubmed">19731042</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, et al. . Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci (2006) 9:917&#x2013;24. doi: 10.1038/nn1715</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1715</ArticleId><ArticleId IdType="pubmed">16732273</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Beers DR, Wen S, Rivera AL, Toennis KM, Appel JE, et al. . Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med (2013) 5(1):64&#x2013;79. doi: 10.1002/emmm.201201544</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201201544</ArticleId><ArticleId IdType="pmc">PMC3569654</ArticleId><ArticleId IdType="pubmed">23143995</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff JR, Simpson EP, Appel SH. Neuroinflammatory mechanisms in amyotrophic lateral sclerosis pathogenesis. Curr Opin Neurol (2018) 31(5):635&#x2013;9. doi:&#xa0;10.1097/WCO.0000000000000599</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000599</ArticleId><ArticleId IdType="pubmed">30048339</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G, Ma H, Qiu L, Li L, Cao Y, Ma J, et al. . Phenotypic and functional switch of macrophages induced by regulatory CD4+CD25+ T cells in mice. Immunol Cell Biol (2011) 89:130&#x2013;42. doi:&#xa0;10.1038/icb.2010.70</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/icb.2010.70</ArticleId><ArticleId IdType="pubmed">20514074</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiemessen MM, Jagger AL, Evans HG, van Herwijnen MJ, John S, Taams LS. CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci USA (2007) 104:19446&#x2013;51. doi:&#xa0;10.1073/pnas.0706832104</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0706832104</ArticleId><ArticleId IdType="pmc">PMC2148309</ArticleId><ArticleId IdType="pubmed">18042719</ArticleId></ArticleIdList></Reference><Reference><Citation>Savage NDL, de Boer T, Walburg KV, Joosten SA, van Meijgaarden K, Geluk A, et al. . Human anti-inflammatory macrophages induce Foxp3+GITR+CD25+ regulatory T cells, which suppress via membrane-bound TGF -1. J Immunol (2008) 181:2220&#x2013;6. doi:&#xa0;10.4049/jimmunol.181.3.2220</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.181.3.2220</ArticleId><ArticleId IdType="pubmed">18641362</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Z, Tsirka SE. Animal models of MS reveal multiple roles of microglia in disease pathogenesis. Neurol Res Int (2011) 2011:383087. doi:&#xa0;10.1155/2011/383087</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2011/383087</ArticleId><ArticleId IdType="pmc">PMC3238412</ArticleId><ArticleId IdType="pubmed">22203900</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Appel SH. Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J Neuroimmune Pharmacol (2013) 8:888&#x2013;99. doi:&#xa0;10.1007/s11481-013-9489-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-013-9489-x</ArticleId><ArticleId IdType="pmc">PMC4126425</ArticleId><ArticleId IdType="pubmed">23881705</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentzos M, Evangelopoulos E, Sereti E, Zouvelou V, Marmara S, Alexakis T, et al. . Alterations of T cell subsets in ALS: a systemic immune activation? Acta Neurol Scand (2012) 125(4):260&#x2013;4. doi:&#xa0;10.1111/j.1600-0404.2011.01528.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.2011.01528.x</ArticleId><ArticleId IdType="pubmed">21651502</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Cheng X, Zhong S, Zhang X, Liu C, Liu F, et al. . Peripheral and central nervous system immune response crosstalk in amyotrophic lateral sclerosis. Front Neurosci (2020) 14:575. doi:&#xa0;10.3389/fnins.2020.00575</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00575</ArticleId><ArticleId IdType="pmc">PMC7308438</ArticleId><ArticleId IdType="pubmed">32612503</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Hooten KG, Sieglaff DH, Zhang A, Kalyana-Sundaram S, et al. . Characterization of gene expression phenotype in amyotrophic lateral sclerosis monocytes. JAMA Neurol (2017) 74:677&#x2013;85. doi: 10.1001/jamaneurol.2017.0357</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.0357</ArticleId><ArticleId IdType="pmc">PMC5822209</ArticleId><ArticleId IdType="pubmed">28437540</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, Gascon R, Miller RG, Gelinas DF, Mass J, Hadlock K, et al. . Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis (sALS). J Neuroimmunol (2005) 159(1-2):215&#x2013;24. doi:&#xa0;10.1016/j.jneuroim.2004.10.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2004.10.009</ArticleId><ArticleId IdType="pubmed">15652422</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Siddiqui S, Gabriely G, Lanser AJ, Dake B, Murugaiyan G, et al. . Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest (2012) 122:3063&#x2013;87. doi:&#xa0;10.1172/jci62636</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci62636</ArticleId><ArticleId IdType="pmc">PMC3428086</ArticleId><ArticleId IdType="pubmed">22863620</ArticleId></ArticleIdList></Reference><Reference><Citation>Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity (2003) 19:71&#x2013;82. doi: 10.1016/S1074-7613(03)00174-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1074-7613(03)00174-2</ArticleId><ArticleId IdType="pubmed">12871640</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol (2008) 8(12):958&#x2013;69. doi:&#xa0;10.1038/nri2448</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2448</ArticleId><ArticleId IdType="pmc">PMC2724991</ArticleId><ArticleId IdType="pubmed">19029990</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiot A, Za&#xef;di S, Iltis C, Ribon M, Berriat F, Schiaffino L, et al. . Modifying macrophages at the periphery has the capacity to change microglial reactivity and to extend ALS survival. Nat Neurosci (2020) 23(11):1339&#x2013;51. doi:&#xa0;10.1038/s41593-020-00718-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00718-z</ArticleId><ArticleId IdType="pubmed">33077946</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan S, Orrell RW. Pathogenesis of amyotrophic lateral sclerosis. Br Med Bull (2016) 119(1):87&#x2013;98. doi:&#xa0;10.1093/bmb/ldw026</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bmb/ldw026</ArticleId><ArticleId IdType="pubmed">27450455</ArticleId></ArticleIdList></Reference><Reference><Citation>Liscic RM, Alberici A, Cairns NJ, Romano M, Buratti E. From basic research to the clinic: innovative therapies for ALS and FTD in the pipeline. Mol Neurodegener (2020) 15(1):31. doi:&#xa0;10.1186/s13024-020-00373-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00373-9</ArticleId><ArticleId IdType="pmc">PMC7268618</ArticleId><ArticleId IdType="pubmed">32487123</ArticleId></ArticleIdList></Reference><Reference><Citation>Doble A. The pharmacology and mechanism of action of riluzole. Neurology. (1996) 47(6 Suppl 4):S233&#x2013;41. doi:&#xa0;10.1212/wnl.47.6_suppl_4.233s</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.47.6_suppl_4.233s</ArticleId><ArticleId IdType="pubmed">8959995</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheah BC, Vucic S, Krishnan AV, Kiernan MC. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr Med Chem (2010) 17(18):1942&#x2013;199. doi: 10.2174/092986710791163939</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/092986710791163939</ArticleId><ArticleId IdType="pubmed">20377511</ArticleId></ArticleIdList></Reference><Reference><Citation>Takei K, Watanabe K, Yuki S, Akimoto M, Sakata T, Palumbo J. Edaravone and its clinical development for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener (2017) 18(sup1):5&#x2013;10. doi: 10.1080/21678421.2017.1353101</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1353101</ArticleId><ArticleId IdType="pubmed">28872907</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D, Mansfield C, Moussy A, Hermine O. ALS clinical trials review: 20 years of failure. are we any closer to registering a new treatment? Front Aging Neurosci (2017) 9:68. doi:&#xa0;10.3389/fnagi.2017.00068</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00068</ArticleId><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Wang F. Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications. Front Immunol (2017) 8:1005. doi:&#xa0;10.3389/fimmu.2017.01005</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01005</ArticleId><ArticleId IdType="pmc">PMC5567007</ArticleId><ArticleId IdType="pubmed">28871262</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo R, Wangqin R, Zhu L, Bi W. Neuroprotective mechanisms of 3-n-butylphthalide in neurodegenerative diseases. BioMed Rep (2019) 11(6):235&#x2013;40. doi:&#xa0;10.3892/br.2019.1246</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/br.2019.1246</ArticleId><ArticleId IdType="pmc">PMC6873419</ArticleId><ArticleId IdType="pubmed">31798868</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng X, Peng Y, Liu M, Cui L. DL-3-n-butylphthalide extends survival by attenuating glial activation in a mouse model of amyotrophic lateral sclerosis. Neuropharmacology. (2012) 62(2):1004&#x2013;10. doi:&#xa0;10.1016/j.neuropharm.2011.10.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2011.10.009</ArticleId><ArticleId IdType="pubmed">22056419</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou QM, Zhang JJ, Li S, Chen S, Le WD. N-butylidenephthalide treatment prolongs life span and attenuates motor neuron loss in SOD1G93A mouse model of amyotrophic lateral sclerosis. CNS Neurosci Ther (2017) 23(5):375&#x2013;85. doi:&#xa0;10.1111/cns.12681</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.12681</ArticleId><ArticleId IdType="pmc">PMC6492644</ArticleId><ArticleId IdType="pubmed">28229532</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M, Yao X, Huang X, Shang H, Fan D, He J, et al. . A multicenter, randomized, double blind, placebo-controlled clinical trial of DL-3-n-butylphthalide in treatment of amyotrophic lateral sclerosis. Randomized Controlled Trial Chin Med J (Engl) 136(3):354&#x2013;356. doi:&#xa0;10.1097/CM9.0000000000002442</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CM9.0000000000002442</ArticleId><ArticleId IdType="pmc">PMC10106172</ArticleId><ArticleId IdType="pubmed">36805548</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilsland LG, Greensmith L. The endocannabinoid system in amyotrophic lateral sclerosis. Curr Pharm Des (2008) 14(23):2306&#x2013;16. doi: 10.2174/138161208785740081</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138161208785740081</ArticleId><ArticleId IdType="pubmed">18781981</ArticleId></ArticleIdList></Reference><Reference><Citation>Giacoppo S, Mazzon E. Can cannabinoids be a potential therapeutic tool in amyotrophic lateral sclerosis? Neural Regener Res (2016) 11(12):1896&#x2013;9. doi: 10.4103/1673-5374.197125</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.197125</ArticleId><ArticleId IdType="pmc">PMC5270417</ArticleId><ArticleId IdType="pubmed">28197175</ArticleId></ArticleIdList></Reference><Reference><Citation>Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, et al. . Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol (1995) 48(3):443&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">7565624</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilsland LG, Dick JR, Pryce G, Petrosino S, Di Marzo D, Baker D, et al. . Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J (2006) 20(7):1003&#x2013;5. doi:&#xa0;10.1096/fj.05-4743fje</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.05-4743fje</ArticleId><ArticleId IdType="pubmed">16571781</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoemaker JL, Seely KA, Reed RL, Crow JP, Prather PL. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem (2007) 101(1):87&#x2013;98. doi: 10.1111/j.1471-4159.2006.04346.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2006.04346.x</ArticleId><ArticleId IdType="pmc">PMC2819701</ArticleId><ArticleId IdType="pubmed">17241118</ArticleId></ArticleIdList></Reference><Reference><Citation>Urbi B, Owusu MA, Hughes I, Katz M, Broadley S, Sabet A. Effects of cannabinoids in amyotrophic lateral sclerosis (ALS) murine models: a systematic review and meta-analysis. J Neurochem (2019) 149(2):284&#x2013;97. doi:&#xa0;10.1111/jnc.14639</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.14639</ArticleId><ArticleId IdType="pubmed">30520038</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuno T, Kurotani T, Komatsu Y, Kawanokuchi J, Kato H, Mitsuma N, et al. . Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology. (2004) 46(3):404&#x2013;11. doi:&#xa0;10.1016/j.neuropharm.2003.09.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2003.09.009</ArticleId><ArticleId IdType="pubmed">14975696</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson B, Maragakis N, Bedlack RS, Goyal N, Meyer JA, Gengeet A, et al. . MN-166 (ibudilast) in amyotrophic lateral sclerosis in a phase IIb/III study: COMBAT-ALS study design. Neurodegener Dis Manage (2021) 11(6):431&#x2013;43. doi:&#xa0;10.2217/nmt-2021-0042</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/nmt-2021-0042</ArticleId><ArticleId IdType="pubmed">34816762</ArticleId></ArticleIdList></Reference><Reference><Citation>Trias E, Ibarburu S, Barreto-N&#xfa;&#xf1;ez R, Babdor J, Maciel TT, Guillo M, et al. . Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis. J Neuroinflammation (2016) 13(1):177. doi:&#xa0;10.1186/s12974-016-0620-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-016-0620-9</ArticleId><ArticleId IdType="pmc">PMC4940876</ArticleId><ArticleId IdType="pubmed">27400786</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora JS, Genge A, Chio A, Estol CJ, Chaverri D, Hern&#xe1;ndez M, et al. . Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Frontotemporal Degener (2020) 21(1-2):5&#x2013;14. doi:&#xa0;10.1080/21678421.2019.1632346</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1632346</ArticleId><ArticleId IdType="pubmed">31280619</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora JS, Bradley WG, Chaverri D, Hern&#xe1;ndez-Barral M, Mascias J, Gamez J, et al. . Long-term survival analysis of masitinib in amyotrophic lateral sclerosis. Ther Adv Neurol Disord (2021) 14:17562864211030365. doi:&#xa0;10.1177/17562864211030365</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/17562864211030365</ArticleId><ArticleId IdType="pmc">PMC8388186</ArticleId><ArticleId IdType="pubmed">34457038</ArticleId></ArticleIdList></Reference><Reference><Citation>Yrj&#xe4;nheikki J, Kein&#xe4;nen R, Pellikka M, H&#xf6;kfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci U S A (1998) 95(26):15769&#x2013;74. doi:&#xa0;10.1073/pnas.95.26.15769</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.26.15769</ArticleId><ArticleId IdType="pmc">PMC28119</ArticleId><ArticleId IdType="pubmed">9861045</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu S, Stavrovskaya IG, Drozda M, Kim BYS, Ona V, Li M, et al. . Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature. (2002) 417(6884):74&#x2013;8. doi:&#xa0;10.1038/417074a</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/417074a</ArticleId><ArticleId IdType="pubmed">11986668</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport (2002) 13:1067&#x2013;70. doi:&#xa0;10.1097/00001756-200206120-00018</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-200206120-00018</ArticleId><ArticleId IdType="pubmed">12060810</ArticleId></ArticleIdList></Reference><Reference><Citation>Kriz J, Nguyen MD, Julien JP. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis (2002) 10(3):268&#x2013;78. doi:&#xa0;10.1006/nbdi.2002.0487</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nbdi.2002.0487</ArticleId><ArticleId IdType="pubmed">12270689</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, et al. . Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol (2007) 6(12):1045&#x2013;53. doi:&#xa0;10.1016/S1474-4422(07)70270-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(07)70270-3</ArticleId><ArticleId IdType="pubmed">17980667</ArticleId></ArticleIdList></Reference><Reference><Citation>McGrath MS, Kahn JO, Herndier BG. Development of WF10, a novel macrophage-regulating agent. Curr Opin Investig Drugs (2002) 3:365&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">12054081</ArticleId></ArticleIdList></Reference><Reference><Citation>McGrath MS, Miller RG. Development of macrophage activation regulator NP001 for ALS. proceedings of the 21st international symposium on ALS/MND, in: Clinical Work in Progress, Orlando, USA, 2010 Dec 11&#x2013;13.</Citation></Reference><Reference><Citation>Miller RG, Zhang R, Block G, Katz J, Barohn R, Kasarskis E, et al. . NP001 regulation of macrophage activation markers in ALS: a phase I clinical and biomarker study. Amyotroph Lateral Scler Frontotemporal Degener (2014) 15(7-8):601&#x2013;9. doi:&#xa0;10.3109/21678421.2014.951940</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.951940</ArticleId><ArticleId IdType="pmc">PMC5524125</ArticleId><ArticleId IdType="pubmed">25192333</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Block G, Katz JS, Barohn RJ, Gopalakrishnan V, Cudkowicz M, et al. . Randomized phase 2 trial of NP001-a novel immune regulator: safety and early efficacy in ALS. Neurol Neuroimmunol Neuroinflamm (2015) 2(3):e100. doi:&#xa0;10.1212/NXI.0000000000000100</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000100</ArticleId><ArticleId IdType="pmc">PMC4396529</ArticleId><ArticleId IdType="pubmed">25884010</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Zhang R, Bracci PM, Azhir A, Richard Barohn R, Bedlack R, et al. . Phase 2B randomized controlled trial of NP001 in amyotrophic lateral sclerosis: pre-specified and post hoc analyses. Muscle Nerve (2022) 66(1):39&#x2013;49. doi:&#xa0;10.1002/mus.27511</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27511</ArticleId><ArticleId IdType="pmc">PMC9327716</ArticleId><ArticleId IdType="pubmed">35098554</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm TH, Draeby D, Owens T. Microglia are required for astroglial toll-like receptor 4 response and for optimal TLR2 and TLR3 response. Glia (2012) 60:630&#x2013;8. doi:&#xa0;10.1002/glia.22296</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22296</ArticleId><ArticleId IdType="pubmed">22271465</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>